Abstract
For patients with liver metastases from gastric cancer (LMGC), combination chemotherapy with fluoropyrimidines and platinum agents has been recognized as standard treatment. However, the prognosis of hepatic progression after first-line treatment failure remains poor. When hepatic progression occurs, hepatic arterial infusion (HAI) chemotherapy may be helpful for preventing disease progression. To retrospectively assess the feasibility and efficacy of HAI chemotherapy using 5-fluorouracil, epirubicin, and mitomycin C (FEM) for patients with LMGC after failure of systemic S-1 plus cisplatin. We reviewed the records of patients who received HAI chemotherapy using FEM for LMGC that progressed during systemic S-1 plus cisplatin treatment while extrahepatic disease was decreased or did not appear. HAI chemotherapy was given as second-line therapy using 5-fluorouracil (330 mg/m(2) weekly), epirubicin (30 or 40 mg/m(2) every 4 weeks), and mitomycin C (2.7 mg/m(2) biweekly). Fourteen patients were analyzed. Toxicity of HAI chemotherapy was generally mild. The objective response rate was 42.9%, including a complete response rate of 14.3%. Median times to hepatic and extrahepatic progression were 9.2 and 7.4 months, respectively. Of 12 p...Continue Reading
References
Jul 1, 1992·Cancer·B van OoijenJ F Lange
Nov 5, 1999·Oncology·T KumadaK Tajima
Feb 3, 2000·Journal of the National Cancer Institute·P TherasseS G Gwyther
Jan 15, 2003·Journal of Vascular and Interventional Radiology : JVIR·Toshihiro TanakaKimihiko Kichikawa
Dec 31, 2003·Journal of the American College of Surgeons·Daniele MarrelliEnrico Pinto
Dec 24, 2005·Journal of Vascular and Interventional Radiology : JVIR·Koichiro YamakadoKan Takeda
Mar 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nancy E KemenyRobert J Mayer
Jun 23, 2007·World Journal of Surgical Oncology·Hitoshi OjimaHiroyuki Kuwano
Dec 21, 2007·AJR. American Journal of Roentgenology·Hiroshi SekiMakoto Shiina
Feb 20, 2008·The Lancet Oncology·Wasaburo KoizumiMasahiro Takeuchi
Feb 29, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S H CheonH C Chung
Jan 28, 2009·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·G A M TiberioS M Giulini
Apr 11, 2009·Journal of Hepato-biliary-pancreatic Surgery·Takashi NomuraWataru Kimura
Oct 13, 2009·The Lancet Oncology·Narikazu BokuUNKNOWN Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group
Feb 18, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jaffer A AjaniSilvia Falcon
Mar 5, 2010·The New England Journal of Medicine·David CunninghamSue Ashley
Aug 24, 2010·Lancet·Yung-Jue BangUNKNOWN ToGA Trial Investigators
Feb 8, 2011·CA: a Cancer Journal for Clinicians·Ahmedin JemalDavid Forman
Oct 20, 2011·The American Journal of Gastroenterology·Barry Schlansky, Amnon Sonnenberg
Nov 15, 2011·Journal of Gastric Cancer·Aesun ShinSohee Park
Mar 14, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jung Hun KangSe Hoon Park
Sep 4, 2012·Acta Radiologica·Hiroshi SekiHiroyuki Ooi
Oct 24, 2012·Radiology·Luigi SolbiatiS Nahum Goldberg
Apr 20, 2013·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·J ChenS Zhang
Oct 8, 2013·Lancet·Charles S FuchsUNKNOWN REGARD Trial Investigators
Dec 18, 2013·The Lancet Oncology·Hugo E R FordUNKNOWN COUGAR-02 Investigators
Mar 4, 2014·Journal of Vascular and Interventional Radiology : JVIR·Riccardo LencioniRobert C G Martin
Citations
Sep 25, 2017·Cancer Medicine·Hui WangJiufei Yu
Mar 5, 2020·Therapeutic Advances in Medical Oncology·Kecheng Zhang, Lin Chen
Jan 11, 2020·Frontiers in Oncology·Zai LuoChen Huang
May 20, 2020·Cancer Management and Research·Weiguang QiangChangping Wu